Heart safety check for new schizophrenia drug

NCT ID NCT05893862

Completed Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) affects heart rhythm in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug causes a dangerous heart rhythm change called QTc prolongation. This was a Phase 1 safety study, not a treatment trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International ( Site 0003)

Glendale, California, 91206, United States
Hassman Research Institute Marlton Site ( Site 0001)

Marlton, New Jersey, 08053, United States
NRC Research Institute ( Site 0004)

Orange, California, 92868, United States
Velocity Clinical Research, Hallandale Beach ( Site 0002)

Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.